Drug
Low Dose BI 3812465
Low Dose BI 3812465: highest development phase Phase 1/2, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Low dose BI 3812465 NCT07553429 | Phase 1/2 | Diabetic Macular Edema |
Latest
No recent events.
Follow Low Dose BI 3812465 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.